Horizon Discovery, a life science spin-out of Cambridge University, signs its second collaboration with pharmaceutical firm AstraZeneca.
Horizon Discovery has partnered with AstraZeneca to explore a range of oncology-relevant genotypes, marking its second collaboration with the pharmaceutical firm. The deal is worth up to $88m in milestone payments to the Cambridge University spin-out, which will also receive an undisclosed payment up front. The announcement builds on a strong 2013 for the company,…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
